The HealthShares Cardiology ETF (Ticker: HRD) seeks to replicate as closely as possible, before expenses, the total return performance of the HealthShares Cardiology Index. The Index is comprised of companies engaged in the research, clinical development and/or commercialization of therapeutic agents for the treatment of cardiological indications including, but not limited to, atherosclerosis, coronary artery disease, congestive heart failure, stroke, hypertension, thrombosis, and restenosis. Companies must have a minimum market capitalization greater than $100 million and less than $15 billion for at least two of the three proceeding quarters. Stocks are equally weighted when the fund is formed and then float with the market thereafter. When the weight of an individual stock reaches 15% of the index value it is adjusted down to 10%, and when a stocks falls to 2.5% it is adjusted up to 5%. S&P is the administrator of HealthShares indexes.
